Crescendo Biologics Limited Email Formats
Biotechnology Research • 
Cambridge, England, United Kingdom • 11-20 Employees
Crescendo Biologics Limited Email Formats
Crescendo Biologics Limited uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@crescendobiologics.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@crescendobiologics.com | 50% |
{first name}{last name} | johndoe@crescendobiologics.com | 50% |
Key Contacts at Crescendo Biologics Limited
Lorraine Thompson
Senior Director Discovery
Eric Rosenfeld
Ceo
Company overview
| Headquarters | Cambridge, England, United Kingdom |
| Phone number | +441223497140 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2009 |
| Employees | 11-20 |
| Socials |
About Crescendo Biologics Limited
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Crescendo Biologics Limited has 6 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Crescendo Biologics Limited's funding history, including investment rounds, total capital raised, and key backers.
Crescendo Biologics Limited Tech Stack
Discover the technologies and tools that power Crescendo Biologics Limited's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Security
JavaScript libraries
Maps
JavaScript libraries
JavaScript libraries
Web servers
Font scripts
JavaScript libraries
Programming languages
Security
Colombia
Qatar
NetherlandsFrequently asked questions
4.8
40,000 users
